Valacyclovir Treatment of Early Symptomatic Alzheimer Disease
JAMA · 10.02.2026 · 335 (6) · 511
DOI: 10.1001/jama.2025.21738 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift JAMA, erschienen am 10.02.2026. Verfasst von D P Devanand und 16 weiteren Autor:innen. Beteiligte Einrichtung: Area Brain Aging and Mental Health, New York State Psychiatric Institute, New York, New York. Hauptthemen laut MEDLINE: Alzheimer Disease, Antiviral Agents, Cognitive Dysfunction, Herpes Simplex. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Importance Neuroscientific, epidemiological, and electronic health record studies implicate herpes simplex virus (HSV) as potentially etiological for Alzheimer disease (AD).
Objective
To compare the efficacy and adverse effects of valacyclovir vs placebo in participants with early symptomatic AD and HSV seropositivity (HSV-1 or HSV-2). Design, Setting, and Participants This randomized clinical trial included adults with a clinical diagnosis of probable AD or a clinical diagnosis of mild cognitive impairment with positive biomarkers for AD, a positive serum antibody test (IgG or IgM) for HSV-1 or HSV-2, and a Mini-Mental State Examination score of 18 to 28. The trial was conducted at 3 US outpatient clinics specializing in memory disorders. Recruitment occurred from January 2018 to May 2022; the last follow-up occurred in September 2024.
Intervention
Either 4 g/d of valacyclovir (n = 60) or matching placebo (n = 60). Main Outcomes and Measures The primary outcome was least-squares mean (LSM) change at 78 weeks in the 11-item Alzheimer’s Disease Assessment Scale Cognitive (ADAS-Cognitive) Subscale score (range, 0-70; higher scores indicate greater impairment). The secondary outcomes were LSM change in the Alzheimer’s Disease Cooperative Study–Activities of Daily Living (ADCS-ADL) Scale score; LSM change in the 18 F-florbetapir amyloid positron emission tomography (PET) standardized uptake value ratio (SUVR; higher scores indicate higher amyloid levels) for 6 brain regions (medial orbitofrontal, anterior cingulate, parietal lobe, posterior cingulate, temporal lobe, and precuneus); and LSM change in 18 F-MK-6240 tau PET medial temporal SUVR (higher scores indicate higher tau levels) for 4 brain regions (amygdala, hippocampus, entorhinal, and parahippocampus). The frequency of adverse events was the safety outcome.
Results
Of the 120 participants (mean age, 71.4 [SD, 8.6] years; 55% were female), 93 (77.5%) completed the trial. At 78 weeks, the LSM change in the 11-item ADAS-Cognitive Subscale score was 10.86 (95% CI, 8.80 to 12.91) in the valacyclovir group vs 6.92 (95% CI, 4.88 to 8.97) in the placebo group, indicating greater cognitive worsening with valacyclovir than placebo (between-group difference, 3.93 [95% CI, 1.03 to 6.83]; P = .01). The LSM change in the ADCS-ADL Scale score at 78 weeks was −13.78 (95% CI, −17.00 to −10.56) in the valacyclovir group vs −10.16 (95% CI, −13.37 to −6.96) in the placebo group (between-group difference, −3.62 [95% CI, −8.16 to 0.93]). At 78 weeks, the LSM change in the 18 F-florbetapir amyloid PET SUVR was 0.03 (95% CI, −0.04 to 0.10) in the valacyclovir group vs 0.01 (95% CI, −0.06 to 0.08) in the placebo group (between-group difference, 0.02 [95% CI, −0.08 to 0.12]). The LSM change in the 18 F-MK-6240 tau PET medial temporal SUVR at 78 weeks was 0.07 (95% CI, −0.06 to 0.19) in the valacyclovir group vs −0.04 (95% CI, −0.15 to 0.07) in the placebo group (between-group difference, 0.11 [95% CI, −0.06 to 0.28]). The most common adverse events were elevated serum creatinine level (5 participants [8.3%] in the valacyclovir group vs 2 participants [3.3%] in the placebo group) and COVID-19 infection (3 [5%] vs 2 [3.3%], respectively). Conclusions and Relevance Valacyclovir was not efficacious with cognitive worsening for the primary outcome and it is not recommended to treat individuals with early symptomatic AD and HSV seropositivity. Trial Registration ClinicalTrials.gov Identifier: NCT03282916
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Area Brain Aging and Mental Health, New York State Psychiatric Institute, New York, New York.
- Department of Psychiatry, Columbia University Medical Center, New York, New York.
- Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York.
- Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, New York.
- Center for Cognitive Neurology, Department of Neurology, Grossman School of Medicine, New York University, New York, New York.
- Departments of Pathology and Psychiatry, Grossman School of Medicine, New York University, New York, New York.
Förderung
- NIA NIH HHS
Zitieren
APA
Devanand, D. P., Wisniewski, T., Razlighi, Q., Qian, M., Wei, R., Andrews, H. F., Acosta, E. P., Bell, K. L., Pelton, G. H., Deliyannides, D., Perrin, A. C., Caccappolo, E., Gershon, A. A., Prasad, K. M., Kreisl, W. C., Mintz, A., & Huey, E. D. (2026). Valacyclovir Treatment of Early Symptomatic Alzheimer Disease. JAMA, 335(6), 511. https://doi.org/10.1001/jama.2025.21738
Vancouver
Devanand DP, Wisniewski T, Razlighi Q, Qian M, Wei R, Andrews HF, et al. Valacyclovir Treatment of Early Symptomatic Alzheimer Disease. JAMA. 2026;335(6):511. doi:10.1001/jama.2025.21738
BibTeX
@article{Devanand2026,
author = {Devanand, D P and Wisniewski, Thomas and Razlighi, Qolamreza and Qian, Min and Wei, Renjie and Andrews, Howard F and Acosta, Edward P and Bell, Karen L and Pelton, Gregory H and Deliyannides, Deborah and Perrin, Allison C and Caccappolo, Elise and Gershon, Anne A and Prasad, K M and Kreisl, William C and Mintz, Akiva and Huey, Edward D},
title = {Valacyclovir Treatment of Early Symptomatic Alzheimer Disease},
journal = {JAMA},
year = {2026},
volume = {335},
number = {6},
pages = {511},
doi = {10.1001/jama.2025.21738}
}
EUVIMED